Company
TransMedics Group, Inc.
Headquarters: Andover, MA, United States
Employees: 148
CEO: Dr. Waleed H. Hassanein
Market Cap
$4.32 Billion
USD as of July 1, 2025
TransMedics Group, Inc. Categories
United States Healthcare Medical DevicesUnited States Healthcare United States Medical Devices
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $233.33 B |
| Boston Scientific Corporation | $154.34 B |
| Stryker | $151.06 B |
| Medtronic | $113.25 B |
| Edwards Lifesciences Corporation | $45.05 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $488.2 M |
| EBITDA | $85.4 M |
| Gross Profit TTM | $290.3 M |
| Profit Margin | 10.03% |
| Operating Margin | 19.12% |
| Quarterly Revenue Growth | 48.20% |
Stocks & Indices
TransMedics Group, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TMDX wb_incandescent